Company intelligence / Profile preview

Legend

Somerset, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Legend Biotech is a global, commercial-stage biotechnology company. Its lead program, ciltacabtagene autoleucel (CARVYKTI®), a BCMA-targeting CAR-T cell therapy, received FDA approval in 2022 for relapsed/refractory multiple myeloma with strong efficacy, including positive 5-year survival data. The company is expanding into additional cell therapy modalities and targets in both hematologic malignancies and solid tumors.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCAR-NK cell therapyCAR-γδ T cell therapyNanobody therapy
Industry: Biotech

Partnerships

Janssen Biotech

Beyond the preview

Go deeper on Legend.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend.

Explore the full profile